In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Florida Medicaid Program Yields Savings Of $42 Mil. After Two Years

Executive Summary

Pfizer is in discussions with Florida's Agency for Health Care Administration about a potential expansion of the company's Medicaid disease management program

You may also be interested in...



Employers Wary Of Disease Management; Pfizer Takes Model To Employees

Insurers appear to be steering employers away from pharmaceutical industry disease management programs with the message that they are not cost effective

Employers Wary Of Disease Management; Pfizer Takes Model To Employees

Insurers appear to be steering employers away from pharmaceutical industry disease management programs with the message that they are not cost effective

Pfizer Ready For Medicare Formularies, CEO Says; Humana JV Begins

Pfizer does not expect implementation of Medicare Rx formularies to have a significant impact on access to its products, CEO Hank McKinnell said during the company's Jan. 19 sales and earnings call

Related Content

UsernamePublicRestriction

Register

PS044978

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel